Change over period: —
NSE · SHILPAMED
SHILPA MEDIC
-14.8% from the 52-week high · +242.8% above the low
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka and currently employs 2,731 full-time employees. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The firm's product range includes oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
The short version. SHILPA MEDIC reported revenue of ₹529 crore for Sep 2026, up 43.0% from a year earlier. Net profit was ₹79 crore (up 79.5% year on year). Return on equity was 9.4% in Mar 2026. Promoter holding was 40.13% in Sep 2026, down 4.10 points over 8 quarters.
1 · The price
How has the stock traded?
SHILPA MEDIC trades 14.8% below its 52-week high and 242.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹529 cr.
Sep 2026 net profit of ₹79 cr.
3.1 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 529 | 466 | 437 | 410 | 370 | 321 | 331 | 319 |
| Net profit | 79 | 101 | 108 | 45 | 44 | 47 | 15 | 32 |
| Net margin % | 15.0 | 21.7 | 24.7 | 10.9 | 11.9 | 14.6 | 4.4 | 10.0 |
| EPS (₹) | 4.05 | 5.16 | 5.51 | 2.28 | 2.25 | 2.4 | 0.74 | 1.63 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1539 | 1286 | 1152 | 1050 | 1146 | 901 | 908 | 733 |
| Net profit | 243 | 78 | 32 | -32 | 61 | 148 | 156 | 112 |
| Net margin % | 15.8 | 6.1 | 2.8 | -3.1 | 5.3 | 16.4 | 17.2 | 15.3 |
| EPS (₹) | 12.44 | 4.0 | 1.84 | -1.87 | 3.49 | 9.06 | 9.58 | 6.88 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 9.4% in Mar 2026; debt to equity is 0.25.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 9.4 | 3.3 | 1.8 | -1.8 |
| Return on capital % | 12.4 | 7.5 | 6.3 | 1.1 |
| EBITDA margin % | 30.6 | 23.8 | 22.3 | 11.2 |
| Net margin % | 15.7 | 6.0 | 2.8 | -3.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 13.2% | 10.7% |
| Profit CAGR | — | 10.5% |
4 · The owners
Who holds it, and are they adding?
Down 4.1 pts over 8 quarters.
Up 2.21 pts over 8 quarters.
Down 0.01 pts over 8 quarters.
+12 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.23 | 44.23 | 44.23 | 44.23 | 40.13 | 40.13 | 40.13 | 40.13 | -4.1 |
| FII | 9.9 | 10.97 | 11.2 | 10.92 | 10.97 | 11.08 | 11.38 | 12.11 | +2.21 |
| DII | 8.27 | 7.55 | 7.46 | 7.67 | 8.33 | 8.58 | 8.05 | 8.26 | -0.01 |
| Public | 37.6 | 37.25 | 37.11 | 37.18 | 40.56 | 40.21 | 40.43 | 39.49 | +1.89 |
Mutual fund holdings · Oct 2026
33 schemes hold this stock
21 the month before.
- SAMCO SPECIAL OPPORTUNITIES FUND3.47% of NAV
- UNION FOCUSED FUND3.26% of NAV
- Bandhan Healthcare Fund3.09% of NAV
- SAMCO ACTIVE MOMENTUM FUND3.03% of NAV
- HDFC Pharma and Healthcare Fund2.92% of NAV
- UNION ACTIVE MOMENTUM FUND2.51% of NAV
- UNION SMALL CAP FUND1.88% of NAV
- ICICI Prudential Exports and Services Fund1.5% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SHILPA MEDIC are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SHILPA MEDIC
What is the SHILPA MEDIC share price?
SHILPA MEDIC (SHILPAMED) last closed at ₹900.70, down 1.6% on the day. Its 52-week range is ₹267.00 to ₹1,073.70.
What is the market cap of SHILPA MEDIC?
SHILPA MEDIC has a market capitalisation of about ₹17,917 crore. Its price-to-earnings ratio is 64.5.
How are SHILPA MEDIC's latest results?
SHILPA MEDIC reported revenue of ₹529 crore for Sep 2026, up 43.0% from a year earlier. Net profit was ₹79 crore (up 79.5% year on year). Return on equity was 9.4% in Mar 2026. Promoter holding was 40.13% in Sep 2026, down 4.10 points over 8 quarters.
Who owns SHILPA MEDIC?
As of Sep 2026, shareholding was: Promoter 40.13%, FII 12.11%, DII 8.26%, Public 39.49%.
How many mutual funds hold SHILPA MEDIC?
33 mutual fund schemes held SHILPA MEDIC in October 2026. That compares with 21 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 03 Oct 2025 · Bonus issue 1:1
- 17 Sep 2025 · Final Dividend - Rs. 1
- 19 Sep 2022 · Dividend - Rs. 1.1
- 20 Sep 2021 · Dividend - Rs. 1.1
- 16 Mar 2020 · Interim Dividend - Rs. 1.1
- 12 Sep 2019 · Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.